@prefix np: . @prefix npx: . @prefix ns1: . @prefix ns2: . @prefix ns3: . @prefix orcid: . @prefix prov: . @prefix rdf: . @prefix rdfs: . @prefix sub: . @prefix this: . @prefix xsd: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { ns1:include . } sub:provenance { sub:_assertion prov:wasGeneratedBy "S&T TWOC Project - version 4", "S&T TWOC version 3" . sub:_version prov:value "2"^^xsd:integer . sub:assertion prov:generatedAtTime "2023-07-20T09:47:22.141392"^^xsd:dateTime; prov:wasAttributedTo orcid:0000-0003-4692-1377; prov:wasDerivedFrom . rdf:OBJECT rdfs:label "antivirals like remdesivir , lopinavir , ritonavir , arbidol , oseltamivir , penciclovir , favipiravir , ganciclovir , and ribavirin ;" . rdf:OBJECT-POSITION rdfs:label "(60, 66)" . rdf:PREDICATE rdfs:label "including" . rdf:PREDICATE-POSITION rdfs:label "67" . rdf:SUBJECT rdfs:label "different pharmacological groups" . rdf:SUBJECT-POSITION rdfs:label "(60, 66)" . rdf:Statement rdfs:label "Results Repurposing of drugs from different pharmacological groups including antivirals like remdesivir, lopinavir, ritonavir, arbidol, oseltamivir, penciclovir, favipiravir, ganciclovir, and ribavirin; other antibiotics like azithromycin, ivermectin, eravacycline, valrubicin, streptomycin, nitazoxanide, teicoplanin, caspofungin, and colistin; and other agents like hydroxychloroquine, chloroquine, tocilizumab, camostat, nafamostat, carfilzomib, interferon, aprepitant, and dexamethasone can be considered for COVID-19 therapy." . rdfs:ABSTRACT-UID ns2:50 "8j41d0a3" . rdfs:TRIPLE-UID ns3:8j41d0a3-TRIPLE-ABSTRACT-1 "8j41d0a3-TRIPLE-ABSTRACT-1" . rdfs:label "lopinavir" . rdfs:label "groups" . } sub:pubinfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "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"; npx:hasSignature "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"; npx:hasSignatureTarget this: . this: prov:wasAttributedTo orcid:0000-0003-4692-1377 . }